AI-Generated Digital Twins Boost Power for MCI Subgroup and Secondary Endpoints in a Simulated Phase 3 Donanemab Trial (TRAILBLAZER-ALZ 2)

By including digital twins as a supercovariate in the analysis of a simulated donanemab trial, we demonstrate digital twins' ability to add power to the MCI subgroup for both primary and secondary endpoints not factored into initial power calculations.